Online and face-to-face programmes to suit your CPD needs, apply now for September 2018
Page URL: https://www.bionews.org.uk/page_95776

Second team corrects sickle-cell mutation using CRISPR

14 November 2016
Appeared in BioNews 877

Researchers have had further success using the CRISPR/Cas9 genome-editing technique to repair the mutation that causes sickle-cell anaemia.

The team used CRISPR/Cas9 to replace the faulty gene in stem cells from patients with the disease. The healthy cells were injected into mice and were still working efficiently 16 weeks later.

'What we've finally shown is that we can do it,' said Dr Matthew Porteus of Stanford University, who led the study. 'It's not just on the chalkboard. We can take stem cells from a patient and correct the mutation and show that those stem cells turn into red blood cells that no longer make sickle haemoglobin.'

Sickle-cell anaemia is an inherited disease in which a mutation in the haemoglobin gene causes red blood cells to become sickle-shaped, rigid and sticky. This causes blockages, reducing blood flow and depriving that part of the body of oxygen, which in turn leads to pain, anaemia and ultimately organ damage.

The research, which was published in Nature, used CRISPR to correct the mutation in haematopoietic stem cells (used to make blood cells) of patients with the disease. The faulty DNA was removed and a correct version of the gene inserted using a virus.

Last month, researchers at the University of California, Berkeley, also used CRISPR to correct the sickle-cell mutation in human stem cells (see BioNews 873). They used the genome-editing technique to both delete the faulty gene and insert the healthy gene, achieving a 25 percent success rate.

In the latest study, the Stanford team created a concentrated pool of stem cells in which 90 percent had the corrected gene. These were injected into mice, and 16 weeks later the healthy stem cells were still thriving.

'These stem cells have a property to be able to get from the blood system into the bone marrow where they then set up shop and start making other blood cells,' said Dr Porteus.

It is not necessary to replace all the diseased blood cells for this procedure to be successful. Dr Porteus says that patients with a proportion of sickle cells below 30 percent will show no symptoms of the disease. Sickle cells have an average life of just ten days compared with 120 days for healthy cells, so the number of corrected red blood cells being produced by the bone marrow soon overtakes the number of sickle cells.

'We think we have a complete data set to present to the FDA (Food and Drug Administration) to say we've done all pre-clinical experiments to show this is ready for a clinical trial,' Dr Porteus told Reuters. The Stanford team hopes to test the technique on the first set of patients in 2018.

SOURCES & REFERENCES
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Nature |  7 November 2016
Gene therapy for sickle cell disease steps closer
Medical News Today |  9 November 2016
More Success Fixing Sickle Cell Gene with CRISPR
The Scientist |  9 November 2016
Researchers take step toward gene therapy for sickle cell disease
Stanford University (press release) |  7 November 2016
Stanford uses CRISPR to correct sickle cell, human trials planned
Reuters |  7 November 2016
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
26 February 2018 - by Anna Mallach 
Genome editing has been used to correct the mutation causing sickle cell disease in stem cells from the blood of patients...
7 August 2017 - by Charlotte Spicer 
Scientists have published their study confirming they are the first to correct a disease-causing mutation in human embryos using genome editing...
6 March 2017 - by Ayala Ochert 
A teenage boy in France appears to have been cured of sickle cell disease using a gene therapy. He has been free of all signs of the disease for 15 months...
9 January 2017 - by Dr Özge Özkaya 
Scientists have discovered a new set of proteins that can block the CRISPR/Cas9 system...
17 October 2016 - by Sarah Gregory 
Researchers have used the CRISPR/Cas9 genome-editing technique to correct the mutation that causes sickle-cell anaemia...
12 September 2016 - by Dr Nicoletta Charolidi 
A genetically engineered virus that triggers the production of an alternative form of haemoglobin has reversed the symptoms of sickle cell disease in mice...
27 June 2016 - by Rachel Reeves 
The first in-human use of the genome-editing technology CRISPR has been approved by a US federal safety board...
27 April 2015 - by Isobel Steer 
Six boys with the inherited immune disorder Wiskott-Aldrich Syndrome (WAS) have been successfully treated with a gene-therapy technique that harnesses a 'tamed' HIV virus...
17 October 2011 - by Mehmet Fidanboylu 
The blood condition sickle cell disease may be reversed by turning off a single gene, according to scientists in the USA. By inactivating a single gene in red blood cells the researchers were able to alleviate symptoms of the disease in mice, offering the hope of a potential new treatment for humans...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.